Zylox-Tonbridge Medical Technology Co., Ltd. Class H (HK:2190) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zylox-Tonbridge Medical Technology Co., Ltd. has reported a significant increase in revenue and profits for the first half of 2024 compared to the same period in 2023, with revenue soaring by 59% and a substantial turnaround to a net profit of RMB 68.9 million. This growth was driven by strong sales growth in both neurovascular and peripheral-vascular interventional devices. The company also highlighted its strategic focus on enhancing medical care accessibility, product innovation, and operational efficiency, which contributed to an impressive surge in non-IFRS adjusted net profit of RMB 78.2 million.
For further insights into HK:2190 stock, check out TipRanks’ Stock Analysis page.
